Volume 10, Issue 4 (2024)
IEM 2024, 10(4): 335-343 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Derakhshan-Nezhad E, Mansoori A. Influenza Co-Infection among COVID-19 Patients in Iran: A Systematic Review. IEM 2024; 10 (4) :335-343
URL: http://iem.modares.ac.ir/article-4-77239-en.html
URL: http://iem.modares.ac.ir/article-4-77239-en.html
1- Student Research Committee, Mashhad University of Medical Sciences, Mashhad, Iran , derakhshanne962@mums.ac.ir
2- Department of Applied Mathematics, School of Mathematical Sciences, Ferdowsi University of Mashhad, Mashhad, Iran
2- Department of Applied Mathematics, School of Mathematical Sciences, Ferdowsi University of Mashhad, Mashhad, Iran
Abstract: (328 Views)
Background: Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is an infectious disease with an unprecedented transmission rate. Considering that there is limited information about the prevalence of influenza co-infection among SARS-CoV-2 positive Iranian patients, and that SARS-CoV-2 co-infection with other respiratory pathogens complicates its diagnosis, prevention, and treatment, this systematic review aimed to evaluate the prevalence of influenza co-infection among SARS-CoV-2 positive Iranian population to facilitate rapid disease management.
Materials & Methods: A comprehensive search was conducted in Web of Science, PubMed, Scopus, and Google Scholar databases using relevant keywords to find all relevant articles published in English from December 2019 to July 2024. Patients of various ages with influenza-SARS-CoV-2 co-infection were evaluated. This study was conducted according to PRISMA (preferred reporting items for systematic reviews and meta-analyses) guidelines.
Findings: Totally, 631 articles were recognized in electronic databases, among them nine articles meeting the inclusion criteria were reviewed in this research. The prevalence of influenza co-infection among SARS-CoV-2 positive patients was 4.38%. The majority of SARS-CoV-2 positive patients were male, while the frequency distribution of influenza-SARS-CoV-2 co-infection was almost the same in both sexes. The viral load was the highest in patients aged 18-60 years.
Conclusion: The findings suggest that the prevalence of influenza co-infection among SARS-CoV-2 positive patients is low. However, the significance of this issue should not be ignored, and influenza vaccination in high-risk groups including hospitalized patients and the elderly is highly recommended due to the probability of serious complications.
Materials & Methods: A comprehensive search was conducted in Web of Science, PubMed, Scopus, and Google Scholar databases using relevant keywords to find all relevant articles published in English from December 2019 to July 2024. Patients of various ages with influenza-SARS-CoV-2 co-infection were evaluated. This study was conducted according to PRISMA (preferred reporting items for systematic reviews and meta-analyses) guidelines.
Findings: Totally, 631 articles were recognized in electronic databases, among them nine articles meeting the inclusion criteria were reviewed in this research. The prevalence of influenza co-infection among SARS-CoV-2 positive patients was 4.38%. The majority of SARS-CoV-2 positive patients were male, while the frequency distribution of influenza-SARS-CoV-2 co-infection was almost the same in both sexes. The viral load was the highest in patients aged 18-60 years.
Conclusion: The findings suggest that the prevalence of influenza co-infection among SARS-CoV-2 positive patients is low. However, the significance of this issue should not be ignored, and influenza vaccination in high-risk groups including hospitalized patients and the elderly is highly recommended due to the probability of serious complications.
Article Type: Systematic Review |
Subject:
Virology
Received: 2024/09/28 | Accepted: 2024/12/20 | Published: 2024/12/20
Received: 2024/09/28 | Accepted: 2024/12/20 | Published: 2024/12/20
References
1. Ghaznavi H, Shirvaliloo M, Sargazi S, Mohammadghasemipour Z, Shams Z, Hesari Z, et al. SARS‐CoV‐2 and influenza viruses: Strategies to cope with coinfection and bioinformatics perspective. Cell Biol Int. 2022;46(7):1009-20. [DOI:10.1002/cbin.11800] [PMID] []
2. Li LQ, Huang T, Wang YQ, Wang ZP, Liang Y, Huang TB, et al. COVID‐19 patients' clinical characteristics, discharge rate, and fatality rate of meta‐analysis. J Med Virol. 2020;92(6):577-85. [DOI:10.1002/jmv.25757] [PMID] []
3. Zoran MA, Savastru RS, Savastru DM, Tautan MN. Assessing the relationship between surface levels of PM2.5 and PM10 particulate matter impact on COVID-19 in Milan, Italy. Sci Total Environ. 2020;738:139825. [DOI:10.1016/j.scitotenv.2020.139825] [PMID] []
4. Drews AL, Atmar RL, Glezen WP, Baxter BD, Piedra PA, Greenberg SB. Dual respiratory virus infections. Clin Infect Dis. 1997;25(6):1421-9. [DOI:10.1086/516137] [PMID] []
5. Gold MS, Sehayek D, Gabrielli S, Zhang X, McCusker C, Ben-Shoshan M. COVID-19 and comorbidities: A systematic review and meta-analysis. Postgrad Med. 2020;132(8):749-55. [DOI:10.1080/00325481.2020.1786964] [PMID]
6. Konala VM, Adapa S, Gayam V, Naramala S, Daggubati SR, Kammari CB, et al. Co-infection with influenza A and COVID-19. Eur J Case Rep Intern. 2020;7(5):001656. [DOI:10.12890/2020_001656] [PMID] []
7. Nuwarda RF, Alharbi AA, Kayser V. An overview of influenza viruses and vaccines. Vaccines. 2021;9(9):1032. [DOI:10.3390/vaccines9091032] [PMID] []
8. Klimov AI, Garten R, Russell C, Barr IG, Besselaar TG, Daniels R, et al. WHO recommendations for the viruses to be used in the 2012 Southern Hemisphere Influenza Vaccine: Epidemiology, antigenic and genetic characteristics of influenza A (H1N1) pdm09, A (H3N2), and B influenza viruses collected from February to September 2011. Vaccine. 2012;30(45):6461-71. [DOI:10.1016/j.vaccine.2012.07.089] [PMID] []
9. Banning M. Influenza: Incidence, symptoms, and treatment. Br J Nurs. 2005;14(22):1192-7. [DOI:10.12968/bjon.2005.14.22.20172] [PMID]
10. Monto AS, Gravenstein S, Elliott M, Colopy M, Schweinle J. Clinical signs and symptoms predicting influenza infection. Arch Intern Med. 2000;160(21):3243-7. [DOI:10.1001/archinte.160.21.3243] [PMID]
11. Iqbal MM, Abid I, Hussain S, Shahzad N, Waqas MS, Iqbal MJ. The effects of regional climatic condition on the spread of COVID-19 at global scale. Sci Total Environ. 2020;739:140101. [DOI:10.1016/j.scitotenv.2020.140101] [PMID] []
12. Sameni F, Hajikhani B, Yaslianifard S, Goudarzi M, Owlia P, Nasiri MJ, et al. COVID-19 and skin manifestations: An overview of case reports/case series and meta-analysis of prevalence studies. Front Med. 2020;7:573188. [DOI:10.3389/fmed.2020.573188] [PMID] []
13. Khorramdelazad H, Kazemi MH, Najafi A, Keykhaee M, Emameh RZ, Falak R. Immuno-pathological similarities between COVID-19 and influenza: Investigating the consequences of co-infection. Microb Pathog. 2020;152:104554. [DOI:10.1016/j.micpath.2020.104554] [PMID] []
14. Dadashi M, Khaleghnejad S, Abedi Elkhichi P, Goudarzi M, Goudarzi H, Taghavi A, et al. COVID-19 and influenza co-infection: A systematic review and meta-analysis. Front Med. 2021;8:681469. [DOI:10.3389/fmed.2021.681469] [PMID] []
15. Yue H, Zhang M, Xing L, Wang K, Rao X, Liu H, et al. The epidemiology and clinical characteristics of co-infection of SARS‐CoV‐2 and influenza viruses in patients during COVID‐19 outbreak. J Med Virol. 2020;92(11):2870-3. [DOI:10.1002/jmv.26163] [PMID] []
16. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. Ann Intern Med. 2009;151(4):264-9. [DOI:10.7326/0003-4819-151-4-200908180-00135] [PMID]
17. Joanna Briggs Institute. JBI critical appraisal checklist for studies reporting prevalence data. Adelaide: University of Adelaide. 2017.
18. Rezaee D, Bakhtiari S, Jalilian FA, Doosti-Irani A, Asadi FT, Ansari N. Coinfection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and influenza virus during the COVID-19 pandemic. Arch Virol. 2023;168(2):53. [DOI:10.1007/s00705-022-05628-y] [PMID] []
19. Alborzi E, Monavari H, Kiani J, Karbalaie Niya MH, Tavakoli A. Low prevalence of SARS-CoV-2 and influenza virus coinfection during COVID-19 disease pandemic in Iran. Iran J Virol. 2022;16(2):35-40.
20. Veisi P, Malekshahi SS, Choobin H, Jabbari MR, Torbati PM. Simultaneous detection of multiple respiratory viruses among SARS-CoV-2-positive and negative patients by multiplex TaqMan one-step real-time PCR. Jundishapur J Microbiol. 2022;15(1):e122090. [DOI:10.5812/jjm.122090]
21. Eilami O, Emami A, Amiripour A, Taghipour K, Hemmati A, Akbarzadeh M, et al. A new perspective: Co-infection of influenza with COVID-19 during the COVID-19 pandemic in southern Iran. 2021:1-14. [DOI:10.21203/rs.3.rs-558099/v1]
22. Pourmomen M, Younesian O, Hosseinzadeh S, Hosseini Alarzi SS, Pourmomen M, Joshaghani H. Frequency of influenza infection in symptomatic patients suspected of having COVID-19. Iran J Med Microbiol. 2023;17(1):112-6. [DOI:10.30699/ijmm.17.1.112]
23. Hashemi SA, Safamanesh S, Ghasemzadeh‐moghaddam H, Ghafouri M, Azimian A. High prevalence of SARS‐CoV‐2 and influenza A virus (H1N1) coinfection in dead patients in northeastern Iran. J Med Virol. 2021;93(2):1008-12. [DOI:10.1002/jmv.26364] [PMID]
24. Hashemi SA, Safamanesh S, Ghafouri M, Taghavi MR, Heydari MS, Ahmadabad HN, et al. Co‐infection with COVID‐19 and influenza A virus in two died patients with acute respiratory syndrome, Bojnurd, Iran. J Med Virol. 2020;92(11):2319-21. [DOI:10.1002/jmv.26014] [PMID] []
25. Heshmat-Ghahdarijani K, Vaseghi G, Nasirian M, Javanmard SH. Co-infection between the severe acute respiratory syndrome coronavirus 2 and the influenza Type B in Isfahan, Iran. J Res Med Sci. 2021;26(1):51. [DOI:10.4103/jrms.JRMS_820_20] [PMID] []
26. Khodamoradi Z, Moghadami M, Lotfi M. Co-infection of coronavirus disease 2019 and influenza A: A report from Iran. Arch Iran Med. 2020;23(4):239-43. [DOI:10.34172/aim.2020.04] [PMID]
27. Akhtar Z, Chowdhury F, Rahman M, Ghosh PK, Ahmmed MK, Islam MA, et al. Seasonal influenza during the COVID-19 pandemic in Bangladesh. PLoS One. 2021;16(8):e0255646. [DOI:10.1371/journal.pone.0255646] [PMID] []
28. Faury H, Courboulès C, Payen M, Jary A, Hausfater P, Luyt C, et al. Medical features of COVID-19 and influenza infection: A comparative study in Paris, France. J Infect. 2021;82(2):e36-9. [DOI:10.1016/j.jinf.2020.08.017] [PMID] []
29. Mukherjee S, Pahan K. Is COVID-19 gender-sensitive? J Neuroimmune Pharmacol. 2021;16(1):38-47. [DOI:10.1007/s11481-020-09974-z] [PMID] []
30. Kim D, Quinn J, Pinsky B, Shah NH, Brown I. Rates of co-infection between SARS-CoV-2 and other respiratory pathogens. JAMA. 2020;323(20):2085-6. [DOI:10.1001/jama.2020.6266] [PMID] []
31. Wu C, Chen X, Cai Y, Zhou X, Xu S, Huang H, et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern Med. 2020;180(7):934-43. [DOI:10.1001/jamainternmed.2020.0994] [PMID] []
32. Ding Q, Lu P, Fan Y, Xia Y, Liu M. The clinical characteristics of pneumonia patients coinfected with 2019 novel coronavirus and influenza virus in Wuhan, China. J Med Virol. 2020;92(9):1549-55. [DOI:10.1002/jmv.25781] [PMID] []
33. Alosaimi B, Naeem A, Hamed ME, Alkadi HS, Alanazi T, Al Rehily SS, et al. Influenza co-infection associated with severity and mortality in COVID-19 patients. Virol J. 2021;18(1):1-9. [DOI:10.1186/s12985-021-01594-0] [PMID] []
34. Yu C, Zhang Z, Guo Y, Shi J, Pei G, Yao Y, et al. Lopinavir/ritonavir is associated with pneumonia resolution in COVID‐19 patients with influenza coinfection: A retrospective matched‐pair cohort study. J Med Virol. 2020;93(1):472-80. [DOI:10.1002/jmv.26260] [PMID] []
35. Cox NJ, Subbarao K. Global epidemiology of influenza: Past and present. Ann Rev Med. 2000;51(1):407-21. [DOI:10.1146/annurev.med.51.1.407] [PMID]
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |